Table 6: Safety parameters of men receiving testosterone treatment (means ± SD).

Visit month Prostate volume (mL) PSA (ng/dL) Residual volume (mL) IPSS score Hemoglobin (g/L) Hematocrit (%) ALT (U/L) AST (U/L)

0 month4519.8 ± 7.4450.96 ± 1.054126.0 ± 17.0453.1 ± 3.04514.6 ± 0.64544.4 ± 2.04544.8 ± 21.74543.7 ± 20.9
12 months1621.9 ± 9.8201.26 ± 1.003918.7 ± 14.2432.1 ± 2.14414.9 ± 0.54446.4 ± 2.24429.6 ± 14.24427.7 ± 12.6
24 months1026.8 ± 10.6171.45 ± 1.053315.5 ± 10.6351.9 ± 1.83615.0 ± 0.43647.7 ± 1.73626.6 ± 11.93626.8 ± 9.6
36 months1226.9 ± 9.2151.40 ± 1.122914.7 ± 9.0321.8 ± 1.43215.1 ± 0.43248.4 ± 1.83224.6 ± 8.43225.6 ± 7.9
48 months829.3 ± 10.691.37 ± 1.192213.0 ± 5.5251.4 ± 0.92515.1 ± 0.42548.4 ± 1.42525.2 ± 5.62525.4 ± 5.9
60 months327.7 ± 16.241.59 ± 1.201013.5 ± 6.7101.8 ± 1.11015.1 ± 0.41048.0 ± 1.81022.8 ± 5.21022.4 ± 4.8
72 months324.3 ± 16.731.04 ± 1.21412.5 ± 5.041.8 ± 1.0415.2 ± 0.3449.0 ± 1.8422.0 ± 3.5421.0 ± 2.9
Difference 60 
months-baseline
3.1 ± 0.510.15 ± 0.092−19.12 ± 2.231−2.5 ± 0.410.54 ± 0.113.8 ± 0.41−28.4 ± 2.51−25.5 ± 2.31

.
Non significant.
PSA: Prostate specific antigen.
IPSS: International prostate symptom score.
ALT: Alanine aminotransferase.
AST: Aspartate aminotransferase.